annual FCF:
-$978.00M-$4.26B(-129.83%)Summary
- As of today (August 18, 2025), VRTX annual free cash flow is -$978.00 million, with the most recent change of -$4.26 billion (-129.83%) on December 31, 2024.
- During the last 3 years, VRTX annual FCF has fallen by -$3.39 billion (-140.61%).
- VRTX annual FCF is now -124.92% below its all-time high of $3.93 billion, reached on December 31, 2022.
Performance
VRTX Free cash flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
quarterly FCF:
$927.40M+$149.20M(+19.17%)Summary
- As of today (August 18, 2025), VRTX quarterly free cash flow is $927.40 million, with the most recent change of +$149.20 million (+19.17%) on June 30, 2025.
- Over the past year, VRTX quarterly FCF has increased by +$4.76 billion (+124.21%).
- VRTX quarterly FCF is now -28.78% below its all-time high of $1.30 billion, reached on September 30, 2024.
Performance
VRTX quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
TTM FCF:
$3.50B+$4.76B(+378.20%)Summary
- As of today (August 18, 2025), VRTX TTM free cash flow is $3.50 billion, with the most recent change of +$4.76 billion (+378.20%) on June 30, 2025.
- Over the past year, VRTX TTM FCF has increased by +$4.93 billion (+345.46%).
- VRTX TTM FCF is now -16.78% below its all-time high of $4.21 billion, reached on September 30, 2023.
Performance
VRTX TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
Range
Earnings dates
Free cash flow Formula
FCF = Cash From Operations − CAPEX
VRTX Free cash flow Trends
PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
---|---|---|---|
1 y1 year | -129.8% | +124.2% | +345.5% |
3 y3 years | -140.6% | -14.6% | -7.6% |
5 y5 years | -165.5% | -9.1% | +36.9% |
VRTX Free cash flow Highs & Lows
PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
---|---|---|---|---|---|---|---|
3 y | 3-year | -124.9% | at low | -28.8% | +124.2% | -16.8% | +345.5% |
5 y | 5-year | -124.9% | at low | -28.8% | +124.2% | -16.8% | +345.5% |
alltime | all time | -124.9% | at low | -28.8% | +124.2% | -16.8% | +345.5% |
VRTX Free cash flow History
Date | Annual | Quarterly | TTM |
---|---|---|---|
Jun 2025 | - | $927.40M(+19.2%) | $3.50B(-378.2%) |
Mar 2025 | - | $778.20M(+58.2%) | -$1.26B(+28.6%) |
Dec 2024 | -$978.00M(-129.8%) | $492.00M(-62.2%) | -$978.00M(-27.6%) |
Sep 2024 | - | $1.30B(-134.0%) | -$1.35B(-5.2%) |
Jun 2024 | - | -$3.83B(-462.0%) | -$1.43B(-141.0%) |
Mar 2024 | - | $1.06B(+793.0%) | $3.48B(+6.1%) |
Dec 2023 | $3.28B(-16.5%) | $118.50M(-90.3%) | $3.28B(-22.0%) |
Sep 2023 | - | $1.23B(+14.2%) | $4.21B(+8.4%) |
Jun 2023 | - | $1.07B(+25.3%) | $3.88B(-0.3%) |
Mar 2023 | - | $857.80M(-17.9%) | $3.89B(-0.9%) |
Dec 2022 | $3.93B(+63.0%) | $1.04B(+15.9%) | $3.93B(+2.9%) |
Sep 2022 | - | $901.30M(-17.0%) | $3.81B(+0.7%) |
Jun 2022 | - | $1.09B(+21.7%) | $3.79B(+54.5%) |
Mar 2022 | - | $892.60M(-4.4%) | $2.45B(+1.8%) |
Dec 2021 | $2.41B(-19.5%) | $933.28M(+6.7%) | $2.41B(+25.5%) |
Sep 2021 | - | $874.70M(-450.4%) | $1.92B(+8.0%) |
Jun 2021 | - | -$249.60M(-129.4%) | $1.78B(-41.7%) |
Mar 2021 | - | $850.13M(+91.5%) | $3.05B(+1.8%) |
Dec 2020 | $2.99B(+100.4%) | $443.84M(-39.4%) | $2.99B(+0.5%) |
Sep 2020 | - | $732.95M(-28.2%) | $2.98B(+16.5%) |
Jun 2020 | - | $1.02B(+28.2%) | $2.56B(+28.9%) |
Mar 2020 | - | $796.25M(+85.5%) | $1.98B(+32.8%) |
Dec 2019 | $1.49B(+27.2%) | $429.25M(+38.2%) | $1.49B(+9.6%) |
Sep 2019 | - | $310.50M(-30.6%) | $1.36B(-3.5%) |
Jun 2019 | - | $447.39M(+45.9%) | $1.41B(+12.3%) |
Mar 2019 | - | $306.74M(+2.6%) | $1.26B(+7.1%) |
Dec 2018 | $1.17B(+100.6%) | $298.86M(-17.1%) | $1.17B(+10.7%) |
Sep 2018 | - | $360.44M(+23.4%) | $1.06B(+55.5%) |
Jun 2018 | - | $292.09M(+30.8%) | $682.12M(+23.0%) |
Mar 2018 | - | $223.38M(+20.8%) | $554.37M(-5.3%) |
Dec 2017 | $585.52M(+226.1%) | $184.91M(-1113.0%) | $585.52M(+10.3%) |
Sep 2017 | - | -$18.25M(-111.1%) | $530.63M(-11.7%) |
Jun 2017 | - | $164.34M(-35.4%) | $600.73M(+30.3%) |
Mar 2017 | - | $254.53M(+95.8%) | $461.18M(+156.9%) |
Dec 2016 | $179.53M(-143.7%) | $130.02M(+150.8%) | $179.53M(+717.7%) |
Sep 2016 | - | $51.84M(+109.2%) | $21.95M(-125.3%) |
Jun 2016 | - | $24.78M(-191.4%) | -$86.69M(-60.6%) |
Mar 2016 | - | -$27.11M(-1.6%) | -$220.11M(-46.4%) |
Dec 2015 | -$410.73M(-27.3%) | -$27.56M(-51.5%) | -$410.73M(-21.0%) |
Sep 2015 | - | -$56.80M(-47.7%) | -$519.97M(-7.2%) |
Jun 2015 | - | -$108.63M(-50.1%) | -$560.11M(-5.2%) |
Mar 2015 | - | -$217.74M(+59.2%) | -$591.10M(+4.7%) |
Dec 2014 | -$564.64M(+448.4%) | -$136.79M(+41.1%) | -$564.64M(+36.6%) |
Sep 2014 | - | -$96.94M(-30.6%) | -$413.47M(+18.6%) |
Jun 2014 | - | -$139.62M(-27.0%) | -$348.76M(+64.6%) |
Mar 2014 | - | -$191.29M(-1429.9%) | -$211.87M(+105.8%) |
Dec 2013 | -$102.96M(-152.6%) | $14.38M(-144.6%) | -$102.96M(-1.6%) |
Sep 2013 | - | -$32.23M(+1081.6%) | -$104.66M(-1000.4%) |
Jun 2013 | - | -$2.73M(-96.7%) | $11.62M(-90.1%) |
Mar 2013 | - | -$82.39M(-749.5%) | $116.94M(-40.3%) |
Dec 2012 | $195.88M(+79.8%) | $12.68M(-84.9%) | $195.88M(-71.1%) |
Sep 2012 | - | $84.05M(-18.1%) | $677.89M(+8.2%) |
Jun 2012 | - | $102.59M(-3069.4%) | $626.55M(+110.6%) |
Mar 2012 | - | -$3.46M(-100.7%) | $297.52M(+173.1%) |
Dec 2011 | $108.96M(-116.2%) | $494.70M(+1412.1%) | $108.96M(-119.2%) |
Sep 2011 | - | $32.72M(-114.4%) | -$566.36M(-26.8%) |
Jun 2011 | - | -$226.43M(+17.9%) | -$773.85M(+16.1%) |
Mar 2011 | - | -$192.02M(+6.3%) | -$666.52M(-1.2%) |
Dec 2010 | -$674.45M(+49.5%) | -$180.62M(+3.3%) | -$674.45M(+11.7%) |
Sep 2010 | - | -$174.78M(+46.7%) | -$603.73M(+32.6%) |
Jun 2010 | - | -$119.10M(-40.4%) | -$455.34M(-0.8%) |
Mar 2010 | - | -$199.95M(+81.9%) | -$458.90M(+1.7%) |
Dec 2009 | -$451.08M(+73.9%) | -$109.91M(+316.5%) | -$451.08M(+1.3%) |
Sep 2009 | - | -$26.39M(-78.5%) | -$445.35M(-20.0%) |
Jun 2009 | - | -$122.65M(-36.2%) | -$556.36M(+63.6%) |
Mar 2009 | - | -$192.14M(+84.4%) | -$340.10M(+31.1%) |
Dec 2008 | -$259.36M | -$104.17M(-24.2%) | -$259.36M(+21.7%) |
Date | Annual | Quarterly | TTM |
---|---|---|---|
Sep 2008 | - | -$137.40M(-246.8%) | -$213.08M(+44.7%) |
Jun 2008 | - | $93.61M(-184.0%) | -$147.25M(-54.3%) |
Mar 2008 | - | -$111.40M(+92.4%) | -$322.35M(+13.1%) |
Dec 2007 | -$284.89M(+419.0%) | -$57.89M(-19.1%) | -$284.89M(+19.5%) |
Sep 2007 | - | -$71.57M(-12.2%) | -$238.31M(+230.1%) |
Jun 2007 | - | -$81.49M(+10.2%) | -$72.18M(+19.3%) |
Mar 2007 | - | -$73.94M(+554.1%) | -$60.51M(+10.2%) |
Dec 2006 | -$54.89M(-71.0%) | -$11.30M(-112.0%) | -$54.89M(-1.5%) |
Sep 2006 | - | $94.55M(-235.4%) | -$55.70M(-73.6%) |
Jun 2006 | - | -$69.82M(+2.2%) | -$211.05M(+5.9%) |
Mar 2006 | - | -$68.32M(+463.9%) | -$199.28M(+5.4%) |
Dec 2005 | -$189.03M(+22.1%) | -$12.12M(-80.1%) | -$189.03M(-7.5%) |
Sep 2005 | - | -$60.79M(+4.7%) | -$204.36M(+8.1%) |
Jun 2005 | - | -$58.05M(-0.0%) | -$189.07M(+19.7%) |
Mar 2005 | - | -$58.07M(+111.6%) | -$157.98M(+2.1%) |
Dec 2004 | -$154.79M(-16.3%) | -$27.45M(-39.7%) | -$154.66M(-3.2%) |
Sep 2004 | - | -$45.51M(+68.8%) | -$159.76M(-1.0%) |
Jun 2004 | - | -$26.95M(-50.8%) | -$161.41M(-11.7%) |
Mar 2004 | - | -$54.75M(+68.2%) | -$182.71M(-1.2%) |
Dec 2003 | -$184.97M(+53.2%) | -$32.55M(-31.0%) | -$184.97M(+4.8%) |
Sep 2003 | - | -$47.15M(-2.3%) | -$176.46M(+10.3%) |
Jun 2003 | - | -$48.26M(-15.3%) | -$160.00M(+16.2%) |
Mar 2003 | - | -$57.01M(+137.2%) | -$137.68M(+14.0%) |
Dec 2002 | -$120.76M(+94.9%) | -$24.04M(-21.7%) | -$120.76M(+82.4%) |
Sep 2002 | - | -$30.68M(+18.3%) | -$66.19M(-31.4%) |
Jun 2002 | - | -$25.94M(-35.3%) | -$96.53M(+15.6%) |
Mar 2002 | - | -$40.09M(-231.3%) | -$83.50M(+34.7%) |
Dec 2001 | -$61.97M(+115.3%) | $30.53M(-150.0%) | -$61.97M(-44.7%) |
Sep 2001 | - | -$61.03M(+372.9%) | -$112.14M(+77.9%) |
Jun 2001 | - | -$12.90M(-30.5%) | -$63.03M(+117.9%) |
Mar 2001 | - | -$18.57M(-5.4%) | -$28.92M(+1.3%) |
Dec 2000 | -$28.79M(-40.0%) | -$19.63M(+64.7%) | -$28.56M(+1061.3%) |
Sep 2000 | - | -$11.92M(-156.2%) | -$2.46M(-74.6%) |
Jun 2000 | - | $21.20M(-216.5%) | -$9.70M(-80.2%) |
Mar 2000 | - | -$18.20M(-381.6%) | -$48.89M(+1.8%) |
Dec 1999 | -$48.02M(+23.3%) | $6.46M(-133.7%) | -$48.02M(-28.8%) |
Sep 1999 | - | -$19.16M(+6.5%) | -$67.44M(+39.0%) |
Jun 1999 | - | -$17.99M(+3.8%) | -$48.51M(+15.9%) |
Mar 1999 | - | -$17.33M(+33.7%) | -$41.86M(+7.5%) |
Dec 1998 | -$38.96M(+150.0%) | -$12.96M(+5611.5%) | -$38.96M(+24.1%) |
Sep 1998 | - | -$227.00K(-98.0%) | -$31.39M(-10.5%) |
Jun 1998 | - | -$11.34M(-21.4%) | -$35.06M(+41.3%) |
Mar 1998 | - | -$14.42M(+167.1%) | -$24.82M(+61.2%) |
Dec 1997 | -$15.58M(-64.8%) | -$5.40M(+38.5%) | -$15.40M(+1.3%) |
Sep 1997 | - | -$3.90M(+254.5%) | -$15.20M(-19.1%) |
Jun 1997 | - | -$1.10M(-78.0%) | -$18.80M(-53.5%) |
Mar 1997 | - | -$5.00M(-3.8%) | -$40.40M(-8.8%) |
Dec 1996 | -$44.24M(+131.7%) | -$5.20M(-30.7%) | -$44.30M(+4.2%) |
Sep 1996 | - | -$7.50M(-67.0%) | -$42.50M(+6.0%) |
Jun 1996 | - | -$22.70M(+155.1%) | -$40.10M(+61.7%) |
Mar 1996 | - | -$8.90M(+161.8%) | -$24.80M(+15.9%) |
Dec 1995 | -$19.09M(+10.5%) | -$3.40M(-33.3%) | -$21.40M(-10.1%) |
Sep 1995 | - | -$5.10M(-31.1%) | -$23.80M(+10.2%) |
Jun 1995 | - | -$7.40M(+34.5%) | -$21.60M(+24.9%) |
Mar 1995 | - | -$5.50M(-5.2%) | -$17.30M(+4.2%) |
Dec 1994 | -$17.28M(-354.7%) | -$5.80M(+100.0%) | -$16.60M(+1975.0%) |
Sep 1994 | - | -$2.90M(-6.5%) | -$800.00K(-144.4%) |
Jun 1994 | - | -$3.10M(-35.4%) | $1.80M(-64.7%) |
Mar 1994 | - | -$4.80M(-148.0%) | $5.10M(-25.0%) |
Dec 1993 | $6.79M(-203.3%) | $10.00M(-3433.3%) | $6.80M(-215.3%) |
Sep 1993 | - | -$300.00K(-250.0%) | -$5.90M(-10.6%) |
Jun 1993 | - | $200.00K(-106.5%) | -$6.60M(-13.2%) |
Mar 1993 | - | -$3.10M(+14.8%) | -$7.60M(+11.8%) |
Dec 1992 | -$6.57M(+70.6%) | -$2.70M(+170.0%) | -$6.80M(+65.9%) |
Sep 1992 | - | -$1.00M(+25.0%) | -$4.10M(+32.3%) |
Jun 1992 | - | -$800.00K(-65.2%) | -$3.10M(+34.8%) |
Mar 1992 | - | -$2.30M | -$2.30M |
Dec 1991 | -$3.85M | - | - |
FAQ
- What is Vertex Pharmaceuticals Incorporated annual free cash flow?
- What is the all time high annual FCF for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated annual FCF year-on-year change?
- What is Vertex Pharmaceuticals Incorporated quarterly free cash flow?
- What is the all time high quarterly FCF for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated quarterly FCF year-on-year change?
- What is Vertex Pharmaceuticals Incorporated TTM free cash flow?
- What is the all time high TTM FCF for Vertex Pharmaceuticals Incorporated?
- What is Vertex Pharmaceuticals Incorporated TTM FCF year-on-year change?
What is Vertex Pharmaceuticals Incorporated annual free cash flow?
The current annual FCF of VRTX is -$978.00M
What is the all time high annual FCF for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high annual free cash flow is $3.93B
What is Vertex Pharmaceuticals Incorporated annual FCF year-on-year change?
Over the past year, VRTX annual free cash flow has changed by -$4.26B (-129.83%)
What is Vertex Pharmaceuticals Incorporated quarterly free cash flow?
The current quarterly FCF of VRTX is $927.40M
What is the all time high quarterly FCF for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high quarterly free cash flow is $1.30B
What is Vertex Pharmaceuticals Incorporated quarterly FCF year-on-year change?
Over the past year, VRTX quarterly free cash flow has changed by +$4.76B (+124.21%)
What is Vertex Pharmaceuticals Incorporated TTM free cash flow?
The current TTM FCF of VRTX is $3.50B
What is the all time high TTM FCF for Vertex Pharmaceuticals Incorporated?
Vertex Pharmaceuticals Incorporated all-time high TTM free cash flow is $4.21B
What is Vertex Pharmaceuticals Incorporated TTM FCF year-on-year change?
Over the past year, VRTX TTM free cash flow has changed by +$4.93B (+345.46%)